Simpson's paradox visualized: The example of the Rosiglitazone meta-analysis

Type: Article

Publication Date: 2008-05-30

Citations: 104

DOI: https://doi.org/10.1186/1471-2288-8-34

Abstract

Simpson's paradox is sometimes referred to in the areas of epidemiology and clinical research. It can also be found in meta-analysis of randomized clinical trials. However, though readers are able to recalculate examples from hypothetical as well as real data, they may have problems to easily figure where it emerges from. First, two kinds of plots are proposed to illustrate the phenomenon graphically, a scatter plot and a line graph. Subsequently, these can be overlaid, resulting in a overlay plot. The plots are applied to the recent large meta-analysis of adverse effects of rosiglitazone on myocardial infarction and to an example from the literature. A large set of meta-analyses is screened for further examples. As noted earlier by others, occurrence of Simpson's paradox in the meta-analytic setting, if present, is associated with imbalance of treatment arm size. This is well illustrated by the proposed plots. The rosiglitazone meta-analysis shows an effect reversion if all trials are pooled. In a sample of 157 meta-analyses, nine showed an effect reversion after pooling, though non-significant in all cases. The plots give insight on how the imbalance of trial arm size works as a confounder, thus producing Simpson's paradox. Readers can see why meta-analytic methods must be used and what is wrong with simple pooling.

Locations

  • BMC Medical Research Methodology - View - PDF
  • PubMed Central - View
  • Europe PMC (PubMed Central) - View - PDF
  • FreiDok plus (Universitätsbibliothek Freiburg) - View - PDF
  • DOAJ (DOAJ: Directory of Open Access Journals) - View
  • PubMed - View

Similar Works

Action Title Year Authors
+ PDF Chat An Alternative to Pooling Kaplan-Meier Curves in Time-to-Event Meta-Analysis 2011 Daniel B. Rubin
+ PDF Chat Evidence Synthesis in Harm Assessment of Medicines Using the Example of Rosiglitazone and Myocardial Infarction 2018 Charlotte Rietbergen
Gudrun Stefansdottir
Hubert G. M. Leufkens
Mirjam J. Knol
Marie L. De Bruin
Irene Klugkist
+ Meta-analysis of incidence of rare events 2012 P. W. Lane
+ PDF Chat Meta-analysis, Simpson's paradox, and the number needed to treat 2002 Douglas G. Altman
Jonathan J Deeks
+ Challenges in meta-analysis of randomized clinical trials for rare harmful cardiovascular events: The case of rosiglitazone 2008 Adrían V. Hernández
Esteban Walker
John P. A. Ioannidis
Michael W. Kattan
+ Meta-analysis for Rare Events in Clinical Trials 2018 Ding‐Geng Chen
Karl E. Peace
+ PDF Chat Comments on ‘Fixed vs random effects meta‐analysis in rare event studies: the rosiglitazone link with myocardial infarction and cardiac death’ by J. J. Shuster, L. S. Jones and D. A. Salmon, <i>Statistics in Medicine</i> 2007; <b>26</b>:4375–4385 2007 James R. Carpenter
Gerta Rücker
Guido Schwarzer
+ Misleading Epidemiological and Statistical Evidence in the Presence of Simpson's Paradox: An Illustrative Study Using Simulated Scenarios of Observational Study Designs 2020 Chanapong Rojanaworarit
+ Meta-Analysis of 'Sparse' Data: Perspectives from the Avandia Cases 2012 Michael O. Finkelstein
Bruce Levin
+ PDF Chat Fixed <i>vs</i> random effects meta‐analysis in rare event studies: The Rosiglitazone link with myocardial infarction and cardiac death 2007 Jonathan J. Shuster
Lynn S. Jones
Daniel A. Salmon
+ PDF Chat Low‐event‐rate meta‐analyses of clinical trials: implementing good practices 2016 Jonathan J. Shuster
Michael Walker
+ Rebuttal to Carpenter <i>et al</i>. comments on ‘Fixed vs. random effects meta‐analysis in rare event studies: The rosiglitazone link with myocardial infarction and cardiac death’ 2008 Jonathan J. Shuster
Lynn S. Jones
Daniel A. Salmon
+ Effectively Combining Independent 2 x 2 Tables for Valid Inferences in Meta Analysis with all Available Data but no Artificial Continuity Corrections for Studies with Zero Events and its Application to the Analysis of Rosiglitazone's Cardiovascular Disease Related Event Data 2007 Lü Tian
Tianxi Cai
Nikita Piankov
Pierre‐Yves Crémieux
L. J. Wei
+ PDF Chat Perspectives on Some Controversies in Cardiovascular Disease Risk Assessment in the Pharmaceutical Development of Glucose-Lowering Medications 2016 Byron J. Hoogwerf
David H. Manner
Haoda Fu
E Moscarelli
Brenda Gaydos
Robert J. Heine
+ Case Study: Evaluation of a meta-analysis of the association between soy protein and cardiovascular disease 2021 S. Stanley Young
Warren B. Kindzierski
Douglas M. Hawkins
Paul Fogel
Terry E. Meyer
+ Comments on ‘Rebuttal to Carpenter <i>et al</i>.’ Comments on ‘Fixed vs random effects meta‐analysis in rare event studies: The rosiglitazone link with myocardial infarction and cardiac death’ by J. J. Shuster, L. S. Jones and D. A. Salmon, <i>Statistics in Medicine</i> 2008; <b>27</b>:3912–3914 2009 Joel Waksman
Christine Kollar
+ PDF Chat Exact and efficient inference procedure for meta-analysis and its application to the analysis of independent 2 x 2 tables with all available data but without artificial continuity correction 2008 Lü Tian
Tianrun Cai
Michael Pfeffer
Nikita Piankov
Pierre‐Yves Crémieux
L. J. Wei
+ PDF Chat Meta-analysis in clinical research 2013 Steven A. Julious
+ PDF Chat Meta-analysis for rare events 2010 Tianxi Cai
Layla Parast
Louise Ryan
+ Simpson’s Paradox 2018 Tamás Rudas

Works That Cite This (25)

Action Title Year Authors
+ Metaanalyse 2023 Antonia Zapf
Christian Röver
+ Methodological Standards for Meta-Analyses and Qualitative Systematic Reviews of Cardiac Prevention and Treatment Studies: A Scientific Statement From the American Heart Association 2017 Goutham Rao
Francisco López-Jiménez
Jack Boyd
Frank d'Amico
Nefertiti Durant
Mark A. Hlatky
George Howard
Kate Kirley
Christopher M. Masi
Tiffany M. Powell‐Wiley
+ Why add anything to nothing? The arcsine difference as a measure of treatment effect in meta‐analysis with zero cells 2008 Gerta Rücker
Guido Schwarzer
James R. Carpenter
Ingram Olkin
+ PDF Chat Bias and precision of methods for estimating the difference in restricted mean survival time from an individual patient data meta-analysis 2016 B. Lueza
Federico Rotolo
Julia Bonastre
Jean‐Pierre Pignon
Stefan Michiels
+ PDF Chat Discussion of “Multivariate Bayesian Logistic Regression for Analysis of Clinical Trial Safety Issues” by W. DuMouchel 2012 Bradley McEvoy
Ram C. Tiwari
+ PDF Chat An Applet for the Investigation of Simpson's Paradox 2013 Kady Schneiter
Jürgen Symanzik
+ PDF Chat Reporting cumulative proportion of subjects with an adverse event based on data from multiple studies 2010 Christy Chuang‐Stein
Mohan Beltangady
+ PDF Chat An Alternative to Pooling Kaplan-Meier Curves in Time-to-Event Meta-Analysis 2011 Daniel B. Rubin
+ Data monitoring committees for clinical trials evaluating treatments of COVID-19 2020 Tobias Mütze
Tim Friede
+ PDF Chat On estimands and the analysis of adverse events in the presence of varying follow‐up times within the benefit assessment of therapies 2018 Steffen Unkel
Marjan Amiri
Norbert Benda
Jan Beyersmann
Dietrich Knoerzer
Katrin Kupas
Frank Langer
Friedhelm Leverkus
Anja H. Loos
Claudia Ose

Works Cited by This (17)

Action Title Year Authors
+ PDF Chat Simpson's paradox and calculation of number needed to treat from meta-analysis 2002 Christopher J Cates
+ PDF Chat Pooling, meta-analysis, and the evaluation of drug safety 2002 Michel Lièvre
Michel Cucherat
Alain Leizorovicz
+ PDF Chat The transitive fallacy for randomized trials: If A bests B and B bests C in separate trials, is A better than C? 2002 Stuart G. Baker
Barnett S. Kramer
+ PDF Chat Randomized trials, generalizability, and meta-analysis: Graphical insights for binary outcomes 2003 Stuart G. Baker
Barnett S. Kramer
+ PDF Chat Meta-analysis, Simpson's paradox, and the number needed to treat 2002 Douglas G. Altman
Jonathan J Deeks
+ PDF Chat Comments on ‘Fixed vs random effects meta‐analysis in rare event studies: the rosiglitazone link with myocardial infarction and cardiac death’ by J. J. Shuster, L. S. Jones and D. A. Salmon, <i>Statistics in Medicine</i> 2007; <b>26</b>:4375–4385 2007 James R. Carpenter
Gerta Rücker
Guido Schwarzer
+ PDF Chat Fixed <i>vs</i> random effects meta‐analysis in rare event studies: The Rosiglitazone link with myocardial infarction and cardiac death 2007 Jonathan J. Shuster
Lynn S. Jones
Daniel A. Salmon
+ PDF Chat NOTES ON THE THEORY OF ASSOCIATION OF ATTRIBUTES IN STATISTICS 1903 G. Undy Yule
+ Quantifying heterogeneity in a meta‐analysis 2002 Julian P. T. Higgins
Simon G. Thompson
+ Empirical evaluation showed that the Copas selection model provided a useful summary in 80% of meta-analyses 2009 James R. Carpenter
Guido Schwarzer
Gerta Rücker
Rita Künstler